Background: Hypophosphatemia is associated with impaired glucose tolerance and insulin resistance in primary hyperparathyroidism. However, little is known about the association between serum phosphate and glucose metabolism in healthy subjects. Methods: We measured fasting serum phosphate levels (SP, normal range 2.6-4.5 mg/dl) and serum calcium (S-Ca, normal range 2.1-2.6 mmol/l) in 881 non-diabetic subjects (341 male/540 female, age: 3871 years, body mass index 25.970.2 kg/m 2 (mean7standard error of the mean). An oral glucose tolerance test (OGTT) with determination of glucose and insulin every 30 min was performed in all subjects. Insulin secretion and insulin sensitivity (IS) were estimated from the OGTT using validated indices. Furthermore, we tested whether serum phosphate predicts glucose tolerance in 115 subjects during a lifestyle intervention program (LIP). Results: Serum phosphate was negatively correlated with 2-h blood glucose levels independent of age, gender and percent body fat (r ¼ À0.13, Po0.0001). This association remained significant after additional adjustment for S-Ca, creatinine and parathyroid hormone. Serum phosphate was positively correlated with IS (r ¼ 0.10, P ¼ 0.0006), but not with insulin secretion. This was independent of age, gender, percent body fat, S-Ca and serum creatinine. In the subjects taking part in the LIP low serum phosphate levels at baseline were associated with higher postprandial glucose levels. Conclusions: In non-diabetic subjects, low serum phosphate levels are associated with high 2-h blood glucose levels and reduced IS. Whether low serum phosphate levels are a cause or a consequence of low IS and impairment of glucose tolerance needs to be tested in further studies.
Introduction
In patients with primary hyperparathyroidism (pHPT) the prevalence of type 2 diabetes (T2DM) is three times higher compared to healthy subjects (Taylor and Khaleeli, 2001) . pHPT is also associated with impaired glucose tolerance (IGT) and reduced insulin sensitivity (IS) (Ljunghall et al., 1983) . The hypophosphatemia present in pHPT and other conditions of various pathogenic origin is thought to be the cause of altered glucose metabolism and impaired responsiveness to insulin (DeFronzo and Lang, 1980) . However, there is also evidence, that phosphate supplementation in glucose intolerant hypophosphatemic patients improves glucose tolerance significantly (Wittmann and Nagy, 1997) . In addition, surgical treatment of pHPT at least partly reverses IGT and insulin resistance in these subjects (Prager et al., 1990; Kautzky-Willer et al., 1992) .
There are several possible mechanisms by which phosphate levels influences glucose metabolism. Phosphate is involved in energy balance and ATP generation. In obese individuals it was shown, that an infusion of several electrolytes/minerals including phosphate was able to increase postprandial thermogenesis (Jaedig et al., 1994) .
Furthermore, in vitro studies have demonstrated that pancreatic islets of phosphate-depleted rats had low ATP levels, elevated cytosolic calcium and impaired glycolytic activity. These islets responded to the phosphate depletion with an impaired insulin secretion. These effects were normalized after phosphate supplementation .
So far, correlations between low serum phosphate and IGT and reduced IS have been shown mainly in states of pronounced phosphate depletion and IGT. However, little is known about these associations in non diabetic individuals with phosphate levels in the normal range.
Therefore the objective of the present study was to determine the association of serum phosphate with glucose tolerance, IS and insulin secretion in a large healthy, nondiabetic population. In addition, we tested whether serum phosphate levels at baseline predict postprandial glucose levels in a longitudinal study.
Materials and methods

Subjects
A total of 881 individuals who participated in the Tübingen Family Study for T2DM were investigated. In that study, primarily normal glucose-tolerant individuals with a family history of T2DM are recruited and metabolically characterized. Recruitment mechanisms include newspaper ads and word-of-mouth proposing diabetes screens. Subjects with T2DM and other severe diseases or with medication (especially drugs affecting glucose metabolism) were excluded from the current analysis.
The local ethics committee had approved all protocols. All subjects gave informed written consent and underwent the standard procedures of the protocols including medical history, medication, physical examination, routine blood tests and an oral glucose tolerance test (OGTT) (data Table 1 ) 332 subjects underwent a hyperinsulinemic euglycemic clamp.
In an additional prospective analysis, 115 subjects taking part in a lifestyle intervention program (TUebingen Lifestyle Intervention Program (TULIP)) were included. They were studied at baseline and after a mean follow-up of 9 months. The subjects were at increased risk for T2DM either because of being overweight (body mass index (BMI)427 kg/m 2 ) or being a first-degree relative of a type 2 diabetic patient or having an IGT or females after gestational diabetes. This program includes the goals of the diabetes prevention study program (Tuomilehto et al., 2001) : reduction of body weight by more than 5%, reduction of dietary intake of fat to less than 30% of calories, reduction of intake of saturated fatty acids to less than 10% of calories, increase of the daily amount of ingested fiber to more than 15 g per 100 kcal and increase of the amount of weekly exercise to more than 3 h per week. To achieve those goals, subjects were looked after by a team of dieticians. During the first 6 months, they had eight sessions with their lifestyle educators where they received individual advice. During each visit participants had to present a 2-day food diary and discussed the results with the dieticians. Diet composition was determined using a validated computer program (DGE-PC 3.0, Deutsche Gesellschaft für Ernährung, Bonn, Germany). In all, 90 subjects presented food diaries on a regular basis (1373 days of food diaries (mean7s.d.)) and were therefore included in the analysis of phosphate intake.
OGTT A standard 75 g OGTT was performed after a 10-h overnight fast, with determination of glucose, insulin and C-peptide at 0, 30, 60, 90, and 120 min. Insulin sensitivity was calculated as proposed by Matsuda and DeFronzo (1999) . First phase insulin secretion was calculated using a validated index (Stumvoll et al., 2000) (1st PH ¼ 1283 þ 1.829 Â Ins 30 À 138.7 Â Gluc 30 þ 3.772 Â Ins 0 ). Percentage of body fat was determined using bioelectrical impedance (RJL Systems, Detroit, MI, USA).
In the prospective study, the OGTT was repeated after a mean follow-up time of 9 months.
Hyperinsulinemic euglycemic clamp
The hyperinsulinemic euglycemic clamp was performed as previously described (Thamer et al., 2003) . The insulin sensitivity index (ISI) (in mmol Â kg À1 Â min À1 Â pM
À1
) for systemic glucose uptake was calculated as the mean infusion rate of glucose (GIR) (in mmol Â kg À1 Â min
) necessary to (Matsuda and DeFronzo, 1999) . b Parathyroid hormone measured n ¼ 348.
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Analytical procedures
Plasma glucose was measured by the glucose-oxidase method (YSI, Yellow Springs Instruments, Yellow Springs, USA). Plasma insulin was determined by a microparticle enzyme immunoassay (Abbott Laboratories, Tokyo, Japan).
Statistical analysis
All data are given as mean7standard error of the mean unless otherwise stated. For variables which were not normally distributed data were logarithmically transformed for further analysis. We used multivariate regression analysis to adjust for the independent effects of covariates. A P-value o0.05 was considered to be statistically significant. All calculations and statistical analyses were performed using the Statistical Package JMP Version 4.0 (SAS Institute Inc., Cary, NC, USA).
Results
Anthropometric data of all subjects are shown in Table 1 . The participants had a mean age of 3871 years and a mean BMI of 25.970.2 kg/m 2 . Out of 881 individuals 770 were normal glucose tolerant and 111 subjects were impaired glucose tolerant.
Association of serum phosphate with BMI and glucose tolerance Serum phosphate was negatively correlated with BMI (r ¼ À0.22, Po0.0001). This was still significant after adjusting for the covariates age and gender (r ¼ À0.17, Po0.0001) (Figure 2 ). Serum phosphate was also negatively correlated with 2-h blood glucose concentration (r ¼ À0.21, Po0.0001). This effect remained significant after adjusting for the covariates gender, age and percent of body fat ( Figure 1a ) (r ¼ À0.13, P ¼ 0.0001, Table 2 ). The additional inclusion of serum calcium (S-Ca), creatinine and parathyroid hormone into the model did not change the significant independent association of serum phosphate with 2 h blood glucose.
Association of serum phosphate with IS and secretion Serum phosphate was positively correlated with IS calculated from the OGTT (r ¼ 0.19, Po0.0001. This effect remained significant after adjusting for the covariates gender, age and percentage of body fat (Figure 1b ) (r ¼ 0.10, Po0.006, Table 3 ). The additional inclusion of S-Ca and creatinine into the model did not change the significant independent association of serum phosphate with IS.
In a subset of 332 subjects which underwent a hyperinsulinemic euglycemic clamp, serum phosphate was also positively associated with IS independent of gender, age, and percentage of body fat (r ¼ 0.12, Po0.03).
There was a significant correlation between serum phosphate and insulin secretion, (r ¼ 0.12, Po0.001) but this correlation was not significant after adjustment for the covariates gender, age and percentage of body fat (Figure 1c ) (r ¼ 0.06, Po0.09). (Matsuda and DeFronzo, 1999) . r and P-values are expressed after adjustment for gender, age and percent body fat. (c) Correlation between serum phosphate and insulin secretion (validated index (Stumvoll et al., 2000) ) r and P-values are expressed after adjustment for gender, age and percent body fat.
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Association of other serum electrolytes with glucose tolerance, IS and secretion Serum potassium was associated with 2 h blood glucose (r ¼ À0.14, P ¼ 0.0001).This association remained significant after adjustment for gender, age and percentage of body fat (r ¼ À0.13, Po0.0001). Serum potassium also showed an association with IS after adjusting for gender, age and percent body fat (r ¼ 0.08, Po0.02). S-Ca, serum sodium and serum magnesium were not associated with 2 h blood glucose levels or IS after adjusting for gender, age and body fatness (all P40.1).
Prospective analysis
The 115 (46 male/69 female) subjects included in the prospective analysis had a mean age of 4671 years. During lifestyle intervention (mean follow-up 971 months) their BMI decreased from 29.970.4 to 29.170.4 kg/m 2 (Po0.0001), their plasma glucose decreased from 6.970.2 to 6.470.2 mmol/l (Po0.0001) and their serum phosphate increased from 3.0870.04 to 3.2370.05 mg/dl (Po0.001). The estimated average daily phosphate intake during 9 months was 1262725 mg per day. The average phosphate intake did not change during the 9 months follow-up (P ¼ 0.9). Model 4 was performed in n ¼ 348 subjects were parathyroid hormone levels were available. In all models, 2-h glucose is the dependent variable. Bold characters display significant associations of phosphate with glucose tolerance. Model 4 was performed in n ¼ 348 subjects were parathyroid hormone levels were available. In all models, insulin sensitivity is the dependent variable. Bold characters display significant associations of phosphate with insulin sensitivity.
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In a multivariate model (Table 4) including gender, age, plasma glucose at baseline and change in body fat we found a significant predictive value of serum phosphate at baseline for postprandial plasma glucose levels at follow-up (Po0.01). Low serum phosphate levels at baseline are associated with higher postprandial plasma glucose levels after a lifestyle intervention. The change in serum phosphate during lifestyle intervention had no significant influence on postprandial plasma glucose.
Discussion
The objective of the present study was to investigate whether serum phosphate levels are associated with glucose tolerance, IS and insulin secretion in healthy non-diabetic subjects. There was a significant association of low serum phosphate concentrations with high 2-h blood glucose levels independent of anthropometric parameters like percent body fat, age and gender. These findings are in line with several other studies which demonstrated a significant correlation between serum phosphate, glucose tolerance (DeFronzo and Lang, 1980; Campillo et al., 1982) and adiposity (Lindgarde and Trell, 1977; Haglin et al., 2001) . Especially the inverse correlation between BMI and low serum phosphate concentrations has been described earlier (Lind et al., 1993) . The mechanism is thought to be attributed by an overconsumption of energy (diet with low nutrient density), in particular an overconsumption of carbohydrates accompanied by low protein intake which is a main source of phosphate (Haglin, 2001) .
The mechanism how hypophosphatemia could influence glucose tolerance is under investigation. Two main factors influencing glucose homeostasis are insulin secretion and IS (Gerich, 1998) . The present study could demonstrate that low serum phosphate levels were associated with a reduced IS estimated from the OGTT. This association was independent of gender, age, percent body fat, S-Ca or serum creatinine. This finding could be confirmed in a smaller group of subjects using the gold standard for measurement of IS, the hyperinsulinemic euglycemic clamp. Moreover, these results are in line with findings in patients with hypophospatemia caused by pHPT (DeFronzo and Lang, 1980; Sowers and Draznin, 1998) .
The results further indicate that there was no significant independent correlation between serum phosphate levels and insulin secretion. These findings are consistent with the results in humans by Paula et al. (1998) . In contrast, Zhou et al. (1991) found a reduced insulin secretion capacity in phosphorus-depleted rats. The different results may be due to the extreme phenotype in the animal model.
Taken together, one explanation for the association of hypophosphatemia with IGT is that hypophophatemia may cause insulin resistance in subjects with disturbed electrolytes metabolism as well as in a healthy population.
Phosphate is needed for ATP generation and therefore seems to be an important component of energy metabolism (Massry et al., 1992; Thompson and Kemp, 1995) . Reduction of serum phosphate could theoretically lead to disturbances of energy metabolism resulting in insulin resistance and IGT. For example, low serum phosphate levels inhibit the phosphorylation of carbohydrate intermediates in glycolysis and gluconeogenesis (Xie et al., 2000) . In addition, limitations of glucose transport across the cell membrane by altering transmembraneous phospholipids are under investigation (Bouche et al., 2004) .
Another explanation for the present findings could be that low serum phosphate levels are not the cause but rather the consequence of increased postprandial blood glucose levels. It is known that osmotic diuresis present in hyperglycemic and acidemic states may cause an increased phosphate excretion due to competition between phosphate and glucose in the proximal tubular system (Simonson and DeFronzo, 1982) . However, since the analysis could confirm the present results also in the subgroup of normal glucosetolerant subjects, the possibility that postprandial hyperglycemia may lead to hypophosphatemia seems to be unlikely. Furthermore, the results demonstrate that low serum phosphate levels in subjects entering a lifestyle intervention are associated with higher postprandial plasma glucose levels at follow-up. Serum phosphate levels increased during lifestyle intervention, however, this increase was not associated with changes in glucose tolerance. Therefore, it seems unlikely that small changes in phosphate intake as part of the lifestyle intervention are responsible for the changes in postprandial plasma glucose levels.
In summary, the present analysis could demonstrate an association of low serum phosphate with high postprandial blood glucose and impaired IS. It can be speculated that insulin resistance and glucose intolerance can be at least worsened by low serum phosphate levels, even in otherwise healthy subjects. However, studies with acute and chronic phosphate supplementation and careful monitoring of glucose homeostasis are needed to finally determine whether hypophosphatemia is causative for hyperglycemia or is rather the consequence of IGT in otherwise healthy subjects. 
